New report digs into top blockbusters and their reliance on patents to block competition
Although “pay-for-delay” agreements and other egregious generic-blocking tactics may be in the rearview mirror, a new report from the nonprofit I-Mak explains how companies are still looking to protect the next generation of blockbusters with piles of new patents.
While some industry insiders point to a broken system that incentivizes these dozens and dozens of new patents — on average there are 74 granted patents on each of America’s 10 top-selling drugs — drugmakers have filed more than 140 patent applications on average per drug, and about two-thirds of those filings came after the approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.